Systematic Optimization of Fragment TLX Ligands toward Agonism and Inverse Agonism

Area of Science:

• Neuroscience
• Molecular Biology
• Drug Discovery

Background:

• The transcription factor tailless homologue (TLX, NR2E1) is crucial for maintaining neural stem cell (NSC) proliferation and neurogenesis.
• TLX activity is modulated by small-molecule ligands, but these are rare, limiting therapeutic development.
• Developing novel TLX modulators is essential for exploring neuroprotective strategies.

Purpose of the Study:

• To develop novel small-molecule ligands that modulate the activity of the transcription factor TLX (NR2E1).
• To identify specific substructures responsible for agonistic and inverse agonistic activity.
• To optimize lead compounds for potent TLX activation and inhibition.

Main Methods:

• Utilized a drug fragment screening hit as a starting point for lead development.
• Performed structural optimization to identify key substructures influencing TLX modulation.
• Validated the binding and activity of the developed ligands.

Main Results:

• Identified novel TLX modulators with tunable activity, ranging from agonism to inverse agonism.
• Developed potent TLX-activating and TLX-inhibiting fragment ligands.
• Demonstrated validated binding and favorable ligand efficiency for further structural development.

Conclusions:

• Successfully developed potent and selective small-molecule TLX modulators.
• These ligands represent valuable tools for studying TLX function in neurogenesis and homeostasis.
• The identified compounds hold promise for the development of new neuroprotective therapies targeting TLX.